Historical Valuation
BridgeBio Pharma Inc (BBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 20.57 is considered Fairly compared with the five-year average of -9.80. The fair price of BridgeBio Pharma Inc (BBIO) is between 51.75 to 506.72 according to relative valuation methord.
Relative Value
Fair Zone
51.75-506.72
Current Price：77.25
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
BridgeBio Pharma Inc (BBIO) has a current Price-to-Book (P/B) ratio of -7.80. Compared to its 3-year average P/B ratio of -4.19 , the current P/B ratio is approximately 85.96% higher. Relative to its 5-year average P/B ratio of 0.94, the current P/B ratio is about -927.41% higher. BridgeBio Pharma Inc (BBIO) has a Forward Free Cash Flow (FCF) yield of approximately -3.89%. Compared to its 3-year average FCF yield of -10.46%, the current FCF yield is approximately -62.86% lower. Relative to its 5-year average FCF yield of -14.84% , the current FCF yield is about -73.81% lower.
P/B
Median3y
-4.19
Median5y
0.94
FCF Yield
Median3y
-10.46
Median5y
-14.84
Competitors Valuation Multiple
AI Analysis for BBIO
The average P/S ratio for BBIO competitors is 34.98, providing a benchmark for relative valuation. BridgeBio Pharma Inc Corp (BBIO.O) exhibits a P/S ratio of 20.57, which is -41.18% above the industry average. Given its robust revenue growth of 4318.01%, this premium appears sustainable.
Performance Decomposition
AI Analysis for BBIO
1Y
3Y
5Y
Market capitalization of BBIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BBIO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BBIO currently overvalued or undervalued?
BridgeBio Pharma Inc (BBIO) is now in the Fair zone, suggesting that its current forward PS ratio of 20.57 is considered Fairly compared with the five-year average of -9.80. The fair price of BridgeBio Pharma Inc (BBIO) is between 51.75 to 506.72 according to relative valuation methord.
What is BridgeBio Pharma Inc (BBIO) fair value?
BBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of BridgeBio Pharma Inc (BBIO) is between 51.75 to 506.72 according to relative valuation methord.
How does BBIO's valuation metrics compare to the industry average?
The average P/S ratio for BBIO's competitors is 34.98, providing a benchmark for relative valuation. BridgeBio Pharma Inc Corp (BBIO) exhibits a P/S ratio of 20.57, which is -41.18% above the industry average. Given its robust revenue growth of 4318.01%, this premium appears sustainable.
What is the current P/B ratio for BridgeBio Pharma Inc (BBIO) as of Jan 11 2026?
As of Jan 11 2026, BridgeBio Pharma Inc (BBIO) has a P/B ratio of -7.80. This indicates that the market values BBIO at -7.80 times its book value.
What is the current FCF Yield for BridgeBio Pharma Inc (BBIO) as of Jan 11 2026?
As of Jan 11 2026, BridgeBio Pharma Inc (BBIO) has a FCF Yield of -3.89%. This means that for every dollar of BridgeBio Pharma Inc’s market capitalization, the company generates -3.89 cents in free cash flow.
What is the current Forward P/E ratio for BridgeBio Pharma Inc (BBIO) as of Jan 11 2026?
As of Jan 11 2026, BridgeBio Pharma Inc (BBIO) has a Forward P/E ratio of -33.67. This means the market is willing to pay $-33.67 for every dollar of BridgeBio Pharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for BridgeBio Pharma Inc (BBIO) as of Jan 11 2026?
As of Jan 11 2026, BridgeBio Pharma Inc (BBIO) has a Forward P/S ratio of 20.57. This means the market is valuing BBIO at $20.57 for every dollar of expected revenue over the next 12 months.